2.43
-0.02 (-0.82%)
| Penutupan Terdahulu | 2.45 |
| Buka | 2.46 |
| Jumlah Dagangan | 75,371 |
| Purata Dagangan (3B) | 114,517 |
| Modal Pasaran | 309,266,528 |
| Harga / Jualan (P/S) | 0.950 |
| Harga / Buku (P/B) | 0.600 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Dec 2025 |
| Margin Keuntungan | -15.50% |
| Margin Operasi (TTM) | -18.31% |
| EPS Cair (TTM) | -0.390 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 30.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 24.95% |
| Nisbah Semasa (MRQ) | 1.35 |
| Aliran Tunai Operasi (OCF TTM) | -8.82 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 8.34 M |
| Pulangan Atas Aset (ROA TTM) | -3.32% |
| Pulangan Atas Ekuiti (ROE TTM) | -6.49% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Household & Personal Products (US) | Menurun | Menurun |
| Household & Personal Products (Global) | Bercampur | Menurun | |
| Stok | Waldencast plc | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.75 |
|
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region. |
|
| Sektor | Consumer Defensive |
| Industri | Household & Personal Products |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 56.95% |
| % Dimiliki oleh Institusi | 25.62% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Zeno Equity Partners Llp | 30 Sep 2025 | 12,252,580 |
| Milestones Administradora De Recursos Ltda. | 30 Sep 2025 | 2,425,677 |
| Mcadam, Llc | 30 Sep 2025 | 63,014 |
| Rhumbline Advisers | 30 Sep 2025 | 57,892 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 4.00 (Canaccord Genuity, 64.61%) | Beli |
| Median | 3.50 (44.03%) | |
| Rendah | 3.00 (Telsey Advisory Group, 23.46%) | Pegang |
| Purata | 3.50 (44.03%) | |
| Jumlah | 1 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 2.56 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Canaccord Genuity | 25 Nov 2025 | 4.00 (64.61%) | Beli | 2.56 |
| Telsey Advisory Group | 25 Nov 2025 | 3.00 (23.46%) | Pegang | 2.56 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 24 Nov 2025 | Pengumuman | Waldencast Announces Q2 2025 Results and Provides Q3 2025 Trading Update |
| 16 Nov 2025 | Pengumuman | Obagi Medical Shares New Clinical Data on Obagi Hyaluronic Acid Injectables and Nu-Cil Scalp Serum at the 2025 American Society for Dermatologic Surgery Annual Meeting |
| 14 Nov 2025 | Pengumuman | Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities |
| 12 Nov 2025 | Pengumuman | Waldencast plc Provides Information Regarding Upcoming Earnings Release Dates |
| 08 Oct 2025 | Pengumuman | Obagi Medical Launches Nu-Cil® BioStim™ Scalp Serum |
| 10 Sep 2025 | Pengumuman | Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |